Company intelligence / Profile preview

Alexza Pharmaceuticals Inc

Mountain View, California, United Statesalexza.com ↗

Ownership: Public · ALXA
Development stage: Commercial

Overview

Alexza has developed and commercialized Adasuve (Staccato loxapine) for the treatment of agitation associated with schizophrenia or bipolar I disorder. The company has multiple other product candidates in various stages of clinical development based on their proprietary Staccato inhalation technology.

Therapeutic areas: GastroenterologyPsychiatryNeurology
Modalities: Small moleculesInhalation drug delivery
Industry: Biotech

Drug pipeline

3 assets

loxapine

Commercial

Indications: schizophrenia, bipolar I disorder, Agitation

2 more assets in the full pipeline.

Partnerships

Endo PharmaceuticalsSymphony Allegro

Beyond the preview

Go deeper on Alexza Pharmaceuticals Inc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alexza Pharmaceuticals Inc.